

HOPE: Health Outcomes and Psychedelic Economics Proposal

Delivering Independent Economic Proof for Breakthrough Mental Health Therapies

The escalating mental health crisis demands urgent, effective solutions. The HOPE initiative unites leading researchers, data analysts, and policy experts to deliver independent, unbiased economic evaluations of five promising psychedelic-assisted therapies (PATs). By rigorously analyzing real-world claims data and comparing PATs to current, often inadequate, standard treatments, HOPE will provide the actionable evidence needed to accelerate policy change, justify coverage, and integrate these transformative therapies into mainstream care, addressing a critical analysis gap often unfilled by government or industry.

The Crisis & The Opportunity

- **Crippling Costs & Suffering:** Mental health and addiction disorders inflict over \$280 billion in direct annual U.S. healthcare costs, plus vast productivity losses. The human cost of inaction is immeasurable.
- **Critical Treatment Gaps:** For 30-50% of individuals, current therapies offer insufficient relief, highlighting an urgent need for superior alternatives.
- **Untapped Potential:** Promising PATs show strong clinical efficacy, yet lack the robust, large-scale economic data required by policymakers and payers to drive widespread adoption and reimbursement.

Our Approach: Rigorous, Comparative Analysis

HOPE will conduct five targeted cost-effectiveness studies:

- | | |
|-------------------------------------|--|
| 1. MDMA for PTSD | 4. Psilocybin for Alcohol Use Disorder |
| 2. Psilocybin for Major Depression | 5. Ibogaine for Opioid Withdrawal |
| 3. Psilocybin for Smoking Cessation | |

Using extensive claims data (Medicare, Medicaid, private insurance, VA), we will quantify the current economic burden of these conditions under standard care. We will then model the potential health gains (QALYs) and net cost savings achievable with PATs, demonstrating their value against existing treatment paradigms.

Why HOPE Matters Now: Driving Tangible Change

- **Compelling, Unbiased Evidence:** HOPE delivers independent research vital for building trust and informing critical decisions, free from commercial influence. Clinical data on PATs suggest significant symptom reduction, lower relapse, and potential for substantial long-term cost savings compared to less effective standard options.
- **Informing Policy & Payer Decisions:** Our analyses will produce 12 peer-reviewed publications and policy briefs, equipping decision-makers (government, CMS, VA, private insurers) with the data needed to drive sustainable mental health reform.
- **Accelerating Patient Access:** By quantifying the compelling economic and health benefits, HOPE will dismantle financial barriers and expedite the integration of these life-changing therapies, benefiting millions.

Funding & Deliverables

- **Project Scope:** A 24-month initiative requiring \$1.847 million.
- **Core Deliverable:** Actionable, independent economic intelligence that empowers leaders to transform mental healthcare, save costs, and improve lives—urgently.